S. Saraf, R. C. Brown, R. W. Hagar, M. Idowu, I. Osunkwo, T. A. Kalfa, F. A. Kuypers, J. Geib, P. Schroeder, E. Wu, P. Kelly, M. J. Telen. P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH. HemaSphere. 2022 Jun 1; 6(Suppl):1377-1378.
2022
https://researcherprofiles.org/profile/425025797